Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
3-(2,4-Dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7-nicotinic acetylcholine receptors and is now in early clinical development for treatment of deficits in neurocognition and sensory gating in schizophrenia. During its initial phase 2 test, functional magnetic resonance imaging (fMRI) studies were conducted to determine whether the drug had its intended effect on hippocampal inhibitory interneurons. Increased hemodynamic activity in the hippocampus in schizophrenia is found during many tasks, including smooth pursuit eye movements, and may reflect inhibitory dysfunction. Placebo and two doses of drug were administered in a random, double-blind crossover design. After the morning drug/placebo ingestion, subjects underwent fMRI while performing a smooth pursuit eye movement task. Data were analyzed from 16 nonsmoking patients, including 7 women and 9 men. The 150-mg dose of DMXB-A, compared with placebo, diminished the activity of the hippocampus during pursuit eye movements, but the 75-mg dose was ineffective. The effect at the 150-mg dose was negatively correlated with plasma drug levels. The findings are consistent with the previously established function of α7-nicotinic receptors on inhibitory interneurons in the hippocampus and with genetic evidence for deficits in these receptors in schizophrenia. Imaging of drug response is useful in planning future clinical tests of this compound and other nicotinic agonists for schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 1×
“CHRNA7, the gene for the a7-nicotinic receptors subunit, has previously been linked to loss of cerebral inhibition in schizophrenia, which supports the role of a7-nicotinic receptors on cerebral inhibitory interneurons in schizophrenia (Freedman et al, 1997).”
ResultSelf-citationInitial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 4×
“DMXB-A was synthesized and placed into capsules as previously described (Freedman et al, 2008).”
BackgroundMethodInfluentialSelf-citationFrazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01187.1998 · Cited by 374 · cited 1×
“A presumptive mechanism of this hyperactivity is the loss of function of hippocampal inhibitory interneurons, which have a markedly high expression of a7-nicotinic receptors, and are depolarized by a7-nicotinic agonists (Breese et al, 1997; Frazier et al, 1998).”
BackgroundSelf-citationComparative pharmacology of rat and human α7 nAChR conducted with net charge analysis
Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249 · cited 2×
“This suggests that at conventional therapeutic doses, DMXB-A and other a7-nicotinic agonists affect cognitive processes by activating only a small fraction of the total number of a7-nicotinic receptors present, at low concentrations where most a7-nicotinic receptors are not occupied by the agonist (Papke and Thinschmi…”
Background
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Kenemans, J. L., & Kähkönen, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.157 · Cited by 104
“Direct augmentation of nicotine receptor activity also restores P50 suppression in schizophrenic patients (Adler et al, 1993), and recently the partial a-7 nicotine agonist DMBX-A (150 mg, 4-weeks regime) reduced hippocampal activation in patients during smooth pursuit (Tregellas et al, 2009).”
Barbier, A. J., Hilhorst, M., Vliet, A. V., Snyder, P., Palfreyman, M. G., Gawryl, M., Dgetluck, N., Massaro, M., Tiessen, R., Timmerman, W., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.013 · Cited by 51
Sinha, N., Karche, N. P., Verma, M. K., Walunj, S. S., Nigade, P. B., Jana, G., Kurhade, S. P., Hajare, A. K., Tilekar, A. R., Jadhav, G. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01569 · Cited by 30
Metadata
- Authors
- Tregellas, J. R., Olincy, A., Johnson, L., Tanabe, J., Shatti, S., Martin, L. F., Singel, D., Du, Y. P., Soti, F., Kem, W. R., & Freedman, R.
- Venue
- Neuropsychopharmacology
- Published
- 2009-12-02
- Volume
- 35
- Issue
- 4
- Pages
- 938-942
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2081672989
- Cited by
- 50
- References
- 4
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia. https://app.cochat.ai/papers/10.1038/npp.2009.196
- The paper
- Tregellas, J. R., Olincy, A., Johnson, L., Tanabe, J., Shatti, S., Martin, L. F., Singel, D., Du, Y. P., Soti, F., Kem, W. R., & Freedman, R. (2010). Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia. Neuropsychopharmacology. https://doi.org/10.1038/npp.2009.196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.